Navigation Links
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
Date:12/9/2009

endogenous expression of the gene encoding vascular endothelial growth factor (VEGF-A). VEGF-A has been demonstrated to have direct angiogenic, neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sensory nerve function from disease-induced nerve damage.

About the Study, SB-509-801

A total of 45 subjects with ALS were enrolled in this trial and randomized into one of two treatment cohorts. The first cohort (38 subjects) received 60 mg of SB-509 in a divided dose into muscles in the neck, arms and legs. The second cohort (7 subjects) received 60 mg of SB-509 in a divided dose into the muscles in the lower limb in both legs. Each subject receives a total of two treatments of 60 mg of SB-509 intramuscularly three months apart on Day 0 and Day 90 and is followed for six months after administration of the final dose.

Details of Presentation of Preliminary Data from SB-509-801 Study

Wednesday, December 9, 2009

  • "Plasmid Gene Transfer of Zinc Finger Protein VEGF-A Transcription Activator (SB-509) for Treatment of Amyotrophic Lateral Sclerosis - A Phase 2 Clinical Trial of SB-509 in ALS." *E. Benaim, S. Hamilton, D. Moore and D. Ando, Sangamo BioSciences, Inc., Richmond, California.

Preliminary data were presented from Sangamo's open-label, repeat dosing, Phase 2 clinical study (SB-509-801) in which subjects with ALS were treated at 0 and 90 days with SB-509 in one of two injection patterns. All subjects will be followed for up to 270 days post initial treatment. A total of 45 subjects are enrolled in the study; data are presented here from 22 subjects up to a time point of 120 days post treatment. There were no drug related severe adverse events and the drug was well-tolerated.

In manual mu
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo Announces Closing of Common Stock Offering
2. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
3. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
4. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
5. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
10. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013 While ... their teens, friends to drink at home under adult ... about drinking, the truth is that there are serious ... Partnership at Drugfree.org and The Treatment Research ... new, interactive web resource for parents and caregivers to ...
(Date:5/22/2013)... 2013 PRNewswire – iBio, Inc. (NYSE ... vaccine candidate for the newly emerged H7N9 influenza ... the iBioLaunch™ platform. This validation milestone was achieved ... sequence information to purification of recombinant protein. ... The iBioLaunch platform eliminates the need to ...
(Date:5/22/2013)... 22, 2013 WomanCare Global recently launched ... an extensive training initiative attended by 90 health ... ) (Logo: http://photos.prnewswire.com/prnh/20101018/DC83896LOGO ) Simplant, ... highly effective subdermal implant composed of two thin, ... (a synthetic form of the hormone progestin). These ...
Breaking Medicine Technology:Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 2Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 3Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 4Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 5Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 6Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 7iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza 2WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile 2
... SAN DIEGO, Feb. 3, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... report its fourth quarter and year-end 2010 financial results after ... will then host a live conference call and webcast to ... afternoon, February 10, 2011 at 5:00 p.m. Eastern Time (2:00 ...
... 2011 SkinMedica, Inc., the fastest-growing professional skin ... that it is introducing a new, fast-acting anti-redness ... in over two decades.  It is the first ... visible redness.     (Photo: ...
Cached Medicine Technology:SkinMedica Launches Redness Relief CalmPlex™ 2SkinMedica Launches Redness Relief CalmPlex™ 3
(Date:5/22/2013)... Brigham and Women,s Hospital (BWH) finds that a genetic ... lung disease, may be effective in identifying individuals at ... presented at the American Thoracic Society International Conference and ... of Medicine on May 22 and will appear ... variant of the MUC5B gene is fairly common, pulmonary ...
(Date:5/22/2013)... from a large observational study reported at ... superior to heparin in the absence of ... patients with non-ST segment elevation acute coronary ... European and US NSTE-ACS guidelines currently recommend ... heparin plus GP IIb/IIIa receptor inhibitors in ...
(Date:5/22/2013)... Purchase, NY (PRWEB) May 22, 2013 ... formed an exclusive partnership with Aurora Financial Systems, ... marketing tool to companies that offer Medicare Advantage ... rewards members for completing 3 out of 12 ... incentive product launched March 2013, and provides an ...
(Date:5/22/2013)... In the past decade, more than 500,000 ... with donated uniforms, shoes, balls and other equipment, thanks ... with manufacturers to provide youth with sporting goods. Now, ... in sports and fitness equipment over 10 years, as ... physical activity. , An inaugural donation of 500 ...
(Date:5/22/2013)... 22, 2013 According to the latest “ ... ” article published recently at FinancesOnline.com the wailing and flailing ... Centers for Disease Control and Prevention 2012 report points ... are overweight, 35.7% are obese, and 6.3% are extremely obese. ... article. In particular, the article focuses on a sector that ...
Breaking Medicine News(10 mins):Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Registry questions superiority of bivalirudin over heparin 2Health News:Integrated Printing Solutions and Aurora Financial Systems, Inc. Create Partnership for Healthcare Incentive Card 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3
... , , LAS VEGAS, ... that expressdelivery.biz is a trusted merchant and its ability to honor ... have been verified by buySAFE. This certificate from the all-bonded online ... reliable and smooth online purchases with bond guarantees of up to ...
... , , , , ... Products Cooperative in Plainview, Minn., got new boots this week as ... contaminants out of the plant. Plainview continues to execute a voluntary ... gums (thickening agents) as the cooperative implements new protocols for the ...
... , , , TORONTO, Aug. ... this weekend. The Bid is delighted to participate in this year,s ... Margarett Best, Ontario Minister of Health Promotion. , , ... , , "Toronto comes alive with the sights ...
... contributes to a great trip, survey finds , SATURDAY, ... satisfying vacation may be to have fewer negative feelings ... a new study says. , Virginia Tech marketing professor ... of satisfaction a traveler experiences during vacation is "strongly ...
... ... rapidly shifting benefits programs. , ... Indianapolis, IN (PRWEB) August 1, 2009 -- Member Firms of United ... organizations, announced that registration for the August webinar titled "Electronic Distribution of SPDs and ...
... 2009) The antidiabetic medication metformin is associated with ... to a new study in Gastroenterology , the ... However, other commonly used therapies, such as insulin or ... the deadly disease. "The current study demonstrated a ...
Cached Medicine News:Health News:US Discount Online Pharmacy Expressdelivery.biz Can Guarantee Safe and Enjoyable Shopping Experience With buySAFE Certificate 2Health News:Plainview Milk Products Cooperative Implements New Employee Boot Policy 2Health News:Toronto 2015 Pan Am Games Bid salutes Caribana 2Health News:Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 2Health News:Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 3Health News:Pancreatic cancer risk decreased by one anti-diabetic therapy, increased by others 2
... BODI™ Dynamic Orthosis is the dynamic way ... over time is proven effective in reducing ... the time of other therapies. Can also ... For all joint stiffness and soft tissue ...
... The Infrapatellar Band uses ... on the patellar tendon helping ... Schlatter and patella tendonitis. Focusing ... the tibial tubercle with less ...
... Provides shoulder ... range of motion ... rotator cuff tears, ... The shoulder brace ...
Shoulder Subluxation Inhibitor (SSI) is an ideal bracing system to keep athletes on the field by reducing the risk of shoulder injury. The SSI is the only brace that allows TOTAL ANTERIOR RANGE OR MO...
Medicine Products: